Literature DB >> 20476923

Antileukotrienes in rhinosinusitis and nasal polyposis.

Isam Alobid1, Sara Cardelús, Cèsar Picado, Joaquim Mullol.   

Abstract

Nasal polyposis is a chronic inflammatory disease of the nasal and paranasal sinus mucosa that, despite different hypotheses of its cause, remains poorly understood. The management of nasal polyposis has been the topic of countless frequent controversial debates for many decades. International guidelines generally suggest that first-line treatment should be based on a medical approach with mainly nasal and oral corticosteroids. Surgical procedures are often viewed as adjunctive to medical therapy. Given that antileukotrienes are currently indicated in the treatment of asthma and allergic rhinitis and there exists an increased leukotriene production in nasal polyps, antileukotrienes, especially montelukast, may represent a potential effective therapy for chronic rhinosinusitis, including nasal polyps.

Entities:  

Year:  2008        PMID: 20476923     DOI: 10.1586/1744666X.4.3.331

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  3 in total

Review 1.  Antileukotrienes in adenotonsillar hypertrophy: a review of the literature.

Authors:  Murat Kar; Niyazi Altıntoprak; Nuray Bayar Muluk; Seckin Ulusoy; Sameer Ali Bafaqeeh; Cemal Cingi
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-03-16       Impact factor: 2.503

Review 2.  Antileukotrienes in upper airway inflammatory diseases.

Authors:  Cemal Cingi; Nuray Bayar Muluk; Kagan Ipci; Ethem Şahin
Journal:  Curr Allergy Asthma Rep       Date:  2015-11       Impact factor: 4.806

Review 3.  Actual concepts in rhinosinusitis: a review of clinical presentations, inflammatory pathways, cytokine profiles, remodeling, and management.

Authors:  Philippe Eloy; Anne Lise Poirrier; Clotilde De Dorlodot; Thibaut Van Zele; Jean Baptiste Watelet; Bernard Bertrand
Journal:  Curr Allergy Asthma Rep       Date:  2011-04       Impact factor: 4.806

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.